Stockscreener 앱 받기
44.42
1.58%
-0.615
전일 마감가:
$45.04
열려 있는:
$45.26
하루 거래량:
10,129
Relative Volume:
0.03
시가총액:
$2.62B
수익:
-
순이익/손실:
$-118.49M
주가수익비율:
-
EPS:
-
순현금흐름:
$-110.57M
1주 성능:
-13.09%
1개월 성능:
-16.31%
6개월 성능:
-9.92%
1년 성능:
+152.45%
1일 변동 폭
$44.11
$46.37
1주일 범위
$44.37
$51.13
52주 변동 폭
$16.39
$72.29
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
APGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| APGE | 44.42 | 2.62B | 0 | -118.49M | -110.57M | 0.00 |
| VRTX | 447.95 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.90 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.67 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.56 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Victory Capital Management Inc. Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times
Apogee Therapeutics Unveils First R&D Day: Spotlight on APG777 and Immunology Pipeline | APGE Stock News - StockTitan
Wedbush Cuts Earnings Estimates for Apogee Therapeutics - MarketBeat
Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Stifel maintains Buy on Apogee Therapeutics with $95 target By Investing.com - Investing.com Australia
Stifel maintains Buy on Apogee Therapeutics with $95 target - Investing.com India
FMR LLC Adjusts Stake in Apogee Therapeutics Inc - GuruFocus.com
Apogee Therapeutics Highlights Pipeline Progress and Financials - TipRanks
APGEApogee Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 Shares - MarketBeat
Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics Inc (APGE) Worth Considering For The Next Few Weeks - Stocks Register
Insider Sale at Apogee Therapeutics Inc (APGE): Chief Medical Of - GuruFocus.com
Apogee Therapeutics chief medical officer sells shares worth $394,041 - Investing.com India
Apogee Therapeutics CEO sells shares worth $888,320 - Investing.com
Apogee Therapeutics chief medical officer sells shares worth $394,041 By Investing.com - Investing.com UK
(APGE) Proactive Strategies - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) and Fennec Pharmaceuticals (NASDAQ:FENC) Financial Contrast - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Mirae Asset Global Investments Co. Ltd. - Defense World
Apogee Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(APGE) Investment Analysis and Advice - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Wedbush Reiterates Outperform Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Unveils Promising Phase 1 Trial Results - TipRanks
Apogee Therapeutics Announces Results Up to 9 Months from - GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel - The Bakersfield Californian
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - StockTitan
Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1%Here's What Happened - MarketBeat
(APGE) Technical Pivots with Risk Controls - Stock Traders Daily
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewswire
11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Down 11.7% in September - MarketBeat
Millennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Analyzing Apogee Therapeutics Inc. (APGE) After Recent Trading Activity - Knox Daily
Ratio Examination: Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now - Insider Monkey
Squarepoint Ops LLC Purchases 25,829 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Inc CEO Michael Henderson Sells 40,000 Shares - GuruFocus.com
Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics CEO sells over $2.2 million in company stock By Investing.com - Investing.com Canada
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):